In a significant development set to reshape India’s precision medicine landscape, Vgenomics, a cutting-edge player in bioinformatics and genomic research, has announced a strategic alliance with Meril Genomics, a key diagnostics and molecular biology innovator. The partnership aims to broaden access to advanced genomic testing solutions for healthcare providers, research institutions, and patients across India.
This collaboration merges Vgenomics’ strengths in AI-powered translational genomics with Meril Genomics’ robust diagnostic infrastructure, creating a powerful synergy to deliver highly accurate, accessible, and timely genomic diagnostics. The alliance is expected to benefit thousands of patients annually by enabling early detection and personalised treatment planning for a variety of conditions.
Expanding Genomic Testing Footprint in India
The joint initiative focuses on three major areas of precision diagnostics:
- Non-Invasive Prenatal Testing (NIPT): Addressing the rising concern of chromosomal disorders such as Down syndrome, particularly among expectant mothers of advanced maternal age, NIPT offers a safer, non-invasive alternative for early prenatal screening. This initiative is poised to improve maternal and neonatal outcomes nationwide.
- Targeted Next-Generation Sequencing (tNGS) for Tuberculosis: With India accounting for over a quarter of the global TB burden, the deployment of tNGS represents a critical intervention. The technology allows for rapid identification of TB strains, expediting treatment initiation and improving disease management.
- Whole Exome Sequencing (WES) for Rare Diseases: With nearly 70 million Indians affected by rare diseases, the partnership will also focus on WES, integrated with advanced AI analytics. This approach will help drastically reduce diagnostic delays, support the development of tailored treatments, and improve patient outcomes in cases that traditionally face lengthy diagnostic journeys.
Read More :- Maintaining Data Consistency with Lab Management Systems in Healthcare
Unified Vision for a Genomics-Enabled Healthcare Future
Dr. Rahila Sardar, CEO of Vgenomics, emphasised the transformative potential of the partnership Together, we envision an India where every citizen has seamless access to advanced genomic diagnostics and precision medicine; Our partnership with Meril Genomics exemplifies our mutual dedication to leveraging genomic science to achieve groundbreaking improvements in patient care and medical outcomes.”
Vivek Shah, CEO of Meril Group, choed the sentiment “By merging our strengths in molecular diagnostics with Vgenomics’ innovative genomic capabilities, we are bridging the gap in genomics diagnostic accessibility. Our efforts will empower clinicians across India, facilitating early and accurate diagnoses. This is a critical step toward advancing precision medicine and aligns perfectly with Meril’s vision of enhancing quality of life through innovative healthcare solutions.”
The collaboration underscores a shared mission to bridge critical diagnostic gaps and foster a more equitable and efficient healthcare ecosystem in India. By combining technological innovation with deep domain expertise, Vgenomics and Meril Genomics are setting a new benchmark for how precision medicine can be scaled for public health impact.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
